NanoLogix, Inc.,, a Nanobiotechnology company engaged in the research,
development and commercialization of technologies for the production of
bacteria and disease testing kits, alternative sources of fuel, cancer therapy
and remediation of toxic materials, announced that it has filed a provisional
patent application for its proprietary method of synergistically combining a
bacteria-based hydrogen production method with excess industrial heat. The
excess heat utilized by this method helps isolate hydrogen producing bacteria
in the bacteria-based hydrogen production method. The bacterial hydrogen
production process uses excess heat that is produced during standard usage of
hydrogen production method, thereby reducing the cost of the hydrogen
production by running two methods simultaneously and conserving energy.
NanoLogix recently announced that preliminary data and results of a study
which confirms laboratory proof-of-concept measurements have shown it possible
to generate hydrogen in high yields via the use and adaptation of its
intellectual property. In this study, the bioreactor produced biogas
consisting of 50% hydrogen by volume, without any trace of methane.
"NanoLogix intends to dominate the patent coverage for a variety of
disruptive technologies at a time when the energy and healthcare industries
are screaming for change," said David McClelland, President of NanoLogix. "We
are seeing confirmation of this by the caliber of companies we are in
discussions with who have expressed interest in our technology, in addition to
significant progress we are making in our research collaborations," he added.
Recently, NanoLogix, Inc. signed a feasibility study with the Department
of Environmental Science and Engineering of Gannon University in Erie, PA to
develop a bioreactor which utilizes NanoLogix's patented bacterial culturing
methods in order to produce hydrogen inexpensively. Hydrogen reacts with
oxygen to yield significant amounts of energy, and has the added benefit of
not producing carbon dioxide as a by-product (the reaction between hydrogen
and oxygen simply generates water vapor). NanoLogix believes they have
discovered the most likely method for low cost production of massive
quantities of hydrogen as an alternate energy source. NanoLogix has
ascertained through its patent counsel that there are eleven relevant U.S.
patents concerning the database containing the terms "Clostridia" and
"Hydrogen Production." NanoLogix presently owns five of these eleven issued
patents.
NanoLogix, Inc., formerly known as Infectech (http://www.infectech.com),
is a technology application innovator of biogas products and services designed
to assist in worldwide energy independence and reduce pollution from
renewable, environmentally-friendly energy sources. NanoLogix is also engaged
in the research and development of diagnostic test kits designed to be used
for the rapid identification of infectious human diseases. The Company's
patents span the identification and antibiotic sensitivity testing of 34
disease-producing bacteria, including M. tuberculosis (TB), Mycobacterium
avium-intracellulare (MAI), pseudomonas, and nocardia. These bacteria are
cited as prominent causes of morbidity and mortality in patients with cancer,
cystic fibrosis, and AIDS. Additionally, NanoLogix owns a patent for the
nontoxic induction of apoptosis in cancer cells utilizing hydrophobic
hydrocarbons. Apoptosis is a method for inducing a genetically based induction
of "cell suicide" in cells. The Company's 31 patents can be viewed by visiting
http://www.infectech.com/intellectual_property.php .
The convergence of science, medicine and technology is on the cusp of
yielding extraordinary breakthroughs. Today, patents that were once designed
to identify bacteria have widespread applications across multiple markets. At
the heart of this convergence is nature. All things begin and end with the
building blocks of life. NanoLogix's portfolio of 31 patents have yielded a
method vital to the development of biophasic system devices intended for
medical purposes to cultivate and identify certain pathogenic microorganisms.
The devices contain one or more components that suppress the growth of certain
microorganisms while either promoting or not affecting the growth of other
microorganisms. The FDA registered devices aid in the diagnosis of disease
caused by the pathogenic microorganisms. Additional products include a method
for low cost hydrogen production, a genomic cancer therapy and methods for
cleaning up toxic environments using bioremediation.
NanoLogix's patents have nanotechnology applications in medical
drugs/devices, bio-defense sensors, hydrogen production, cancer treatment and
bioremediation. Nanotechnology applications include Biochips embedded in
small transportable devices for rapid bacteria identification of disease
causing pathogens, and Bio Micro Electro Mechanical Systems ("BioMEMS") for
rapid environmental microbial monitoring with bio-defense implications. Its
hydrogen bioreactor research is designed to assist in worldwide energy
independence and reduce pollution using renewable, environmentally-friendly
energy sources. NanoLogix's FDA registered diagnostic test kits are designed
to be used for the rapid identification of infectious human diseases and
identify 34 disease-producing bacteria, including Tuberculosis (TB),
Mycobacterium avium-intracellulare (MAI), Pseudomonas, and Nocardia. These
bacteria are cited as prominent causes of morbidity and mortality in patients
with cancer, cystic fibrosis, and AIDS, as well as in patients undergoing
surgery. Additionally, NanoLogix owns a patent for the nontoxic induction of
apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a
method for inducing a genetically based induction of "cell suicide" in cells.
It therefore serves as the foundation for cancer therapy. NanoLogix's other
patents include technology designed for use in the bioremediation of
contaminated soil and water.
